ArticleNature2022
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,062 papers.
0numbers the graph read from it
0cells of the map it votes in
1,062citing papers in PubMed
95.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,062 citing papers in PubMed, 1,594 citations in OpenAlex.
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases · 2026Trial
- Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.Frontiers in public health · 2025Trial
- An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.Nature medicine · 2024Trial
- Disulfide bonds stabilize the SARS-CoV-2 RBD and preserve binding to ACE2 following thermal denaturation.Bioscience reports · 2026Article
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- mRNA Vaccines Targeting the Conserved SARS-CoV-2 Fusion Machinery Elicit Cross-Variant and Robust Immunity.Vaccines · 2026Article
- Article
- Article
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models.Viruses · 2026Article
- Serum Escape Landscape of SARS-CoV-2 Omicron JN.1 and XEC RBD Under COVID-19 Vaccine Breakthrough Immunity in China.Microorganisms · 2026Article
- ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses.Journal of virology · 2026Article
- Variant-specific spike conformational dynamics shape memory B cell selection during recall.bioRxiv : the preprint server for biology · 2026Article
- Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.Scientific reports · 2026Article
- Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.Archives of virology · 2026Article
- MAAD: multidimensional antiviral antibody database.Protein & cell · 2026Article
- Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.Journal of medical virology · 2026Article
- Long-term cross-variant Fc-mediated immune responses against SARS-CoV-2 induced by a heterologous adenoviral/inactivated virus prime-boost vaccination strategy.NPJ vaccines · 2026Article
1,002 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
32 authors at 8 institutions in 2 countries.
Delphine Planas *Virus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.
Nell Saunders *Virus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.ORCID http://orcid.org/0000-0002-0872-1529
Piet Maes *Department of Microbiology, Laboratory of Clinical and Epidemiological Virology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-4571-5232
Florence Guivel-BenhassineVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.
Cyril PlanchaisHumoral Immunology Laboratory, Institut Pasteur, Université de Paris, INSERM U1222, Paris, France.
Julian BuchrieserVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.ORCID http://orcid.org/0000-0003-4790-7577
William-Henry BollandVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.
Françoise PorrotVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.ORCID http://orcid.org/0000-0001-8995-3614
Isabelle StaropoliVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.
Frederic LemoineHub de Bioinformatique et Biostatistique, Institut Pasteur, Université de Paris, CNRS USR 3756, Paris, France.ORCID http://orcid.org/0000-0001-9576-4449
Hélène PéréLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
David VeyerLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
Julien PuechLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
Julien RodaryLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
Guy BaeleDepartment of Microbiology, Laboratory of Clinical and Epidemiological Virology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1915-7732
Simon DellicourDepartment of Microbiology, Laboratory of Clinical and Epidemiological Virology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-9558-1052
Joren RaymenantsLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Sarah GorissenLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Caspar GeenenLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-2778-6344
Bert VanmechelenDepartment of Microbiology, Laboratory of Clinical and Epidemiological Virology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Tony Wawina-BokalangaDepartment of Microbiology, Laboratory of Clinical and Epidemiological Virology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Joan Martí-CarrerasDepartment of Microbiology, Laboratory of Clinical and Epidemiological Virology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Lize CuypersDepartment of Laboratory Medicine, National Reference Centre for Respiratory Pathogens, University Hospitals Leuven, Leuven, Belgium.
Aymeric SèveService de Maladies Infectieuses, CHR d'Orléans, Orléans, France.
Laurent HocquelouxService de Maladies Infectieuses, CHR d'Orléans, Orléans, France.ORCID http://orcid.org/0000-0002-2264-4822
Thierry PrazuckService de Maladies Infectieuses, CHR d'Orléans, Orléans, France.
Félix A ReyStructural Virology Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France.ORCID http://orcid.org/0000-0002-9953-7988
Etienne Simon-LoriereG5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université de Paris, Paris, France.ORCID http://orcid.org/0000-0001-8420-7743
Timothée BruelVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France. timothee.bruel@pasteur.fr.ORCID http://orcid.org/0000-0002-3952-4261
Hugo MouquetHumoral Immunology Laboratory, Institut Pasteur, Université de Paris, INSERM U1222, Paris, France. hugo.mouquet@pasteur.fr.
Emmanuel AndréLaboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. emmanuel.andre@uzleuven.be.
Olivier SchwartzVirus and Immunity Unit, Institut Pasteur, Université de Paris, CNRS UMR3569, Paris, France. olivier.schwartz@pasteur.fr.ORCID http://orcid.org/0000-0002-0729-1475
Centre National de la Recherche Scientifique · FRKU Leuven · BERega Institute for Medical Research · BEInserm · FRCentre hospitalier universitaire d'Orléans · FRHôpital Européen Georges-Pompidou · FRInstitut Pasteur · FRUniversité Libre de Bruxelles · BE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and South Africa
Indexed as
Immunization, SecondaryAdultAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBelgiumBNT162 VaccineChAdOx1 nCoV-19ConvalescenceCOVID-19FemaleHumansImmune EvasionMaleMutationNeutralization TestsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.